Role combination drug therapy class IC antiarrhythmic agent mexiletine ventricular tachycardia combination mexiletine class IC antiarrhythmic agent encainide propafenone flecainide electrophysiologic patients history sustained ventricular tachycardia tachycardia inducible therapy class IC drug control drug-free state patients inducible ventricular tachycardia mean cycle length ms monotherapy IC tachycardia inducible patient significant increase cycle length ms effective refractory period ventricle Treatment mexiletine oral intravenous electrophysiologic testing Ventricular tachycardia patient noninducible patient aggravation tachycardia patients inducible average cycle length ms NS Nine patients rate slowing average cycle length ventricular tachycardia group ms average effective refractory period combination therapy ms drug therapy ms therapy class IC drug ms mean follow-up interval months patients treatment ventricular tachycardia 